Acadia Pharmaceuticals
S&P 600
$27.83
+0.32%
Delayed · cached 15 min
Fair value analysis
ACAD
Acadia Pharmaceuticals
$27.83
Close used for this calculation
$28.78Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
79/100
Quality radar
Consensus fair value
$28.78
Near FV▲ +3.4% against the close used
Model range $11.19 – $69.00
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$11.19Fair value$28.78Bull$69.00
FairClose
52-week traded range
52W low $20.0652W high $30.57
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
Acadia Pharmaceuticals closed at $27.83, 3.3% below the consensus fair value of $28.78 drawn from 7 valuation models.
Financial DNA score 79/100 — Strong. P/E of 12.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$12.28
-55.9%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
P/E Fair Value
$46.00
+65.3%
EPS × 20x (sector P/E)
EPS=2.3, Sector P/E=20x
Peter Lynch (PEG)
$69.00
+147.9%
EPS × Growth% (PEG = 1 is fair)
EPS=2.3, g=30%
EV/EBITDA
$11.19
-59.8%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=105.68M
Book Value (P/B)
$45.22
+62.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=7.56, ROE=29.9%, g=6%, r=10%
Reverse DCF
$27.83
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 0.3% | Historical: 40%
Margin of Safety
$21.86
-21.5%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=29.14, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.